BRCA1 and ovarian cancer: In 2017 to 2018, niraparib [42], olaparib [43] and rucaparib [44] have been approved for maintenance therapy in patients with platinum-sensitive ovarian cancer due to the observations that PARPi maintenance therapy significantly improves the PFS of patients with ovarian cancer regardless of BRCA1/2 status.